Hypofractionated Radiation Therapy for Early Glottic Cancer: Preliminary Results.
- Author:
Hong Gyun WU
;
Semie HONG
;
Seong Soo SHIN
;
Charn Il PARK
- Publication Type:Review
- MeSH:
Appointments and Schedules;
Biopsy;
Female;
Follow-Up Studies;
Hoarseness;
Humans;
Male;
Neoplasm Metastasis;
Recurrence;
Treatment Failure
- From:The Journal of the Korean Society for Therapeutic Radiology and Oncology
2001;19(4):301-305
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was performed for the evaluation of the feasibility and toxicity of hypofractionated radiation therapy for early glottic cancer METHODS AND MATERIALS: From February 1999 to February 2000, 20 patients with histologically confirmed Stage I, II glottic cancer were enrolled into this study. There were 18 males and 2 females, the median age of the patients was 59 years. The distribution of stage distribution was as follows; T1aN0-16 patients, T1bN0-1 patient, T2N0-3 patients. Eighteen patients underwent laryngomicroscopic biopsy only, and two patients underwent laser cordectomy. All patients received radical radiation therapy (2.5 Gy per fraction, 24 fractions, total 60 Gy). Median duration of treatment was 36 days (range 31-45 days). RESULTS: Radiation therapy were well tolerated. Most common acute reactions were odynophagia and hoarseness, and these reactions resolved after radiation therapy. There were one case of RTOG grade 3 odynophagia (5%), six cases of grade 3 hoarseness (30%). Response of radiation therapy was evaluated one month after completion of treatment. All patients revealed complete response. During follow up, total three cases of treatment failure were detected. two cases were local recurrence in 10 and 13 months of radiation therapy and one case was local recurrence and distant metastasis in 2 months of radiation therapy CONCLUSION: This hypofractionated radiation therapy schedule was feasible and effective for control of early glottic cancer. But longer follow up time would be required to assess the long-term disease control and the late complication by shortening radiation therapy duration.
